Cargando…
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study
Background: Sodium selenite at high dose exerts antitumor effects and increases efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the safety and efficacy of intravenous administered sodium selenite in cancer patients’ refractory to cytostatic drugs in a phase I tria...
Autores principales: | Brodin, Ola, Eksborg, Staffan, Wallenberg, Marita, Asker-Hagelberg, Charlotte, Larsen, Erik H., Mohlkert, Dag, Lenneby-Helleday, Clara, Jacobsson, Hans, Linder, Stig, Misra, Sougat, Björnstedt, Mikael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488827/ https://www.ncbi.nlm.nih.gov/pubmed/26102212 http://dx.doi.org/10.3390/nu7064978 |
Ejemplares similares
-
Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells
por: Misra, Sougat, et al.
Publicado: (2016) -
Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite
por: Brodin, Ola, et al.
Publicado: (2020) -
Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites
por: Breuer, Olof, et al.
Publicado: (2023) -
Selenium induces a multi-targeted cell death process in addition to ROS formation
por: Wallenberg, Marita, et al.
Publicado: (2014) -
Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial
por: Razaghi, Ali, et al.
Publicado: (2022)